Evaluation of the significance of mutation and expression of the specific chimeric oncogene Bcr-abl p210 in chronic myeloid leukemia in the Uzbek population
Keywords:
tyrosine kinase inhibitors, BCR-ABL1, chronic myeloid leukemia.Abstract
The use of tyrosine kinase inhibitors (TKI) considerably improved the
prognosis for most patients with chronic myeloid leukemia (CML). However, the issue of
resistance to TKI therapy remains a challenge. At present, much attention is paid to the
study of molecular genetic profile of tumor cells in CML patients and the role of somatic
mutations in various genes, beyond BCR-ABL1, in the development of resistance to TKI
therapy. New data emerge on the frequency of somatic mutations in various genes by the
time of primary diagnosis of CML, commonly in the chronic phase, and on clonal changes
during treatment, also when the disease progresses. Of particular interest is the role of
somatic gene mutations in the transformation of CML into accelerated phase and blast
crisis. Special importance is attributed to the time between the detection of somatic
mutations and the registration of disease progression. This review focuses on the results of
recent and most relevant studies of molecular genetic profile of CML patients at various
disease stages. These studies aim to reveal the associations between somatic mutations in
genes and a response to TKI therapy, as well as to assess the prognostic value of the
mutations detected upon primary diagnosis and CML therapy.
References
Cortes J, Pavlovsky C, Saussele S. Chronic myeloid leukaemia. Lancet.
;398(10314):1914–26. doi: 10.1016/S0140-6736(21)01204-6.
Hehlmann R. Chronic Myeloid Leukemia in 2020. Hemasphere. 2020;4(5):E468. doi:
1097/HS9.0000000000000468.
Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry:
incidence and clinical characteristics of 2904 CML patients in 20 European countries.
Leukemia. 2015;29(6):1336–43. doi: 10.1038/leu.2015.73.
Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid
leukemia. Blood. 2009;113(8):1619–30. doi: 10.1182/blood-2008-03144790.
Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous
leukaemia. Nat Rev Cancer. 2005;5(3):172–83. doi: 10.1038/nrc1567.
Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic
myelogenous leukaemia. Nature. 1985;315(6020):550–4. doi: 10.1038/315550a0.
Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. Tyrosine kinase
inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499–512.
Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, et al.
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic
leukemia: a cancer and leukemia group B study (8762). Blood 1992;80:2983–90.
Куликов С.М., Виноградова О.Ю., Челышева Е.Ю. и др. Заболеваемость
хроническим миелолейкозом в 6 регионах России по данным популяционного
исследования 2009–2012 гг. Терапевтический архив. 2014;86(7):24–30. [Kulikov
S.M., Vinogradova O.Yu., Chelysheva E.Yu., et al. The incidence of chronic myeloid
leukemia in 6 regions of Russia according to the population-based study of 2009–2012.
Terapevticheskii arkhiv. 2014;86(7):24–30. (In Russ)]
